While CIPN occurs via direct neurotoxicity with disruption of microtubules, mitochondrial damage and axonal degeneration [11], PD-1 inhibitor-associated peripheral neuropathy is thought to be driven by the therapy’s immunomodulating effects and can frequently lead to demyelination noted on electromyography (EMG) or nerve conduction studies (NCS) [12]. The gene discussed is PDCD1; the disease is peripheral neuropathy.